Sight-saving uveitis treatment could help more patients, trial suggests
UK study indicates current eligibility criteria for adalimumab may be too narrow, potentially excluding many patients at risk of blindness.
By Laura Medhurst
••2 min read
AI
Generic image of an inflamed human eye, with blurred medical equipment in the background.
A UK clinical trial has indicated that the drug adalimumab could protect the sight of a significantly larger group of patients suffering from the eye inflammation condition uveitis than currently recognised.
Research findings published in eClinical Medicine suggest that the National Institute for Health and Care Excellence (NICE) criteria for adalimumab eligibility should be broadened. Uveitis, an inflammation inside the eye, is a leading cause of blindness in high-income countries, despite being considered rare.
The ASTUTE trial, a collaboration between Oxford University Hospitals and Bristol NHS Foundation Trust involving 18 UK hospitals, initially treated all non-infectious uveitis patients with adalimumab for 16 weeks. Subsequently, patients whose eyes responded well were randomised to continue on the drug or receive a dummy injection. After a year, only 31.4% of those on adalimumab experienced a relapse or required further treatment, compared to 59% on the placebo.
Current NICE guidelines, established before extensive trials in this patient group, only fund adalimumab for non-infectious uveitis under strict conditions. Approximately 85% of patients in the ASTUTE trial did not meet these criteria. For these 'excluded' patients, continued adalimumab treatment reduced the risk of treatment failure by 63%, with benefits comparable to those for all trial participants.
“
"We now have UK trial evidence, from NHS clinics and patients, that the rules are drawn in the wrong place."
Side effects were found to be no more common with adalimumab than with the placebo. Health economists from the University of Oxford assessed the cost-effectiveness, finding an additional annual cost of £662 per patient, with the cost of preventing one episode of treatment failure at £2,320. The trial utilised a more affordable biosimilar version of adalimumab, commonly used by the NHS.
“
"That design let us show, cleanly, that stopping the drug in people who are doing well on it leads to relapse in most of them. The implication for practice is straightforward: when it works, it needs to be continued, and in many more patients than are currently eligible."
Patients were involved in the trial's design, advising on study measures and participant requirements. The ASTUTE trial received support from the Birdshot Uveitis Society, the NIHR Health Technology Assessment Programme, and the NIHR Biomedical Research Centres at Moorfields and Oxford. The research team has submitted these eligibility findings to NICE.
“
"They deserve to know that it has produced an answer that could change who gets treated."